Profile data is unavailable for this security.
About the company
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
- Revenue in SEK (TTM)100.00k
- Net income in SEK-190.35m
- Incorporated2016
- Employees7.00
- LocationFlerie ABSkeppsbron 16STOCKHOLM 111 30SwedenSWE
- Phone+46 812203850
- Fax+46 850884739
- Websitehttps://www.flerie.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Natac Natural Ingredients SA | 519.15m | 99.98m | 3.14bn | 172.00 | 51.13 | 6.32 | 17.86 | 6.04 | 0.0124 | 0.0124 | 0.0742 | 0.1004 | 0.4869 | 0.1089 | 9.76 | 315,106.60 | 9.51 | -- | 11.90 | -- | 98.12 | -- | 19.53 | -- | 0.44 | -- | 0.5921 | -- | 3,152.85 | -- | 308.68 | -- | -- | -- |
Duopharma Biotech Bhd | 1.81bn | 119.69m | 3.21bn | 1.94k | 26.85 | 1.91 | 13.79 | 1.77 | 0.0514 | 0.0514 | 0.7776 | 0.7214 | 0.5771 | 1.99 | 3.69 | 385,581.40 | 3.81 | 5.54 | 4.62 | 6.91 | 35.98 | 39.77 | 6.61 | 9.49 | 2.93 | 4.03 | 0.4302 | 50.09 | 1.15 | 7.16 | -24.91 | 2.02 | -15.67 | -5.76 |
Hanshang Group Co Ltd | 1.93bn | 31.57m | 3.24bn | 2.38k | 98.97 | 1.29 | -- | 1.68 | 0.0757 | 0.0757 | 4.46 | 5.83 | 0.3718 | 2.65 | 8.25 | 552,235.40 | 0.3729 | 2.00 | 0.6192 | 3.89 | 55.85 | 57.24 | 1.00 | 4.89 | 0.2774 | 1.84 | 0.3798 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
PharmaSGP Holding SE | 1.25bn | 206.93m | 3.25bn | 93.00 | 15.67 | 8.75 | 10.35 | 2.60 | 1.52 | 1.52 | 9.15 | 2.72 | 0.8223 | 1.04 | 8.57 | 1,233,225.00 | 13.64 | 13.70 | 18.34 | 19.98 | 90.91 | 90.20 | 16.59 | 17.56 | 1.54 | 14.98 | 0.6823 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
Flerie AB | 100.00k | -190.35m | 3.28bn | 7.00 | -- | 0.0075 | -- | 32,787.89 | -102.92 | -102.92 | 0.0333 | 5,610.13 | 0.00004 | -- | -- | 14,285.71 | -7.86 | -37.64 | -7.99 | -41.14 | -126,944.00 | -450.51 | -190,353.00 | -454.62 | -- | -- | 0.0003 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
Alliance Pharma plc | 2.49bn | -455.66m | 3.30bn | 290.00 | -- | 1.09 | -- | 1.33 | -0.0622 | -0.0622 | 0.3378 | 0.4124 | 0.4016 | 2.72 | 4.67 | 627,215.80 | -7.36 | -0.5982 | -8.08 | -0.6566 | 59.42 | 62.45 | -18.34 | -1.80 | 2.06 | 4.45 | 0.3218 | -- | 7.92 | 8.86 | -56.24 | -- | -25.01 | -- |
Frontier Biotechnologies Inc | 180.31m | -464.26m | 3.40bn | 395.00 | -- | 1.96 | -- | 18.84 | -0.8445 | -0.8445 | 0.328 | 3.16 | 0.057 | 1.43 | 2.91 | 311,049.00 | -14.67 | -14.05 | -17.86 | -15.78 | 31.82 | 2.35 | -257.47 | -450.08 | 2.11 | -- | 0.2763 | -- | 34.82 | 126.63 | 7.79 | -- | 28.13 | -- |
Cipher Pharmaceuticals Inc | 230.21m | 234.83m | 3.42bn | 9.00 | 14.31 | 3.48 | 13.87 | 14.85 | 1.23 | 1.23 | 1.22 | 5.06 | 0.2539 | 1.46 | 4.62 | 3,382,695.00 | 25.90 | 21.53 | 28.35 | 27.40 | 81.08 | 83.58 | 102.01 | 57.31 | 10.59 | -- | 0.0033 | 0.00 | 2.36 | -1.44 | -23.48 | 76.18 | -53.51 | -- |
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 31 Dec 2023 | 52.31m | 0.67% |
Ponderus Invest ABas of 31 Dec 2023 | 6.20m | 0.08% |
SEB Investment Management ABas of 28 Jun 2024 | 2.10m | 0.03% |
Atlant Fonder ABas of 31 Jul 2024 | 1.07m | 0.00% |